CAS Number 410074-73-6 ChemSpider 9833390 KEGG D10088 | PubChem CID 11658655 UNII GE0J375F8F Molar mass 228.118 g/mol | |
![]() | ||
Legal status US: Investigational New Drug |
Amitifadine (am-i-TIF-a-deen) (DOV-21,947 or EB-1010) is an antidepressant drug being developed by Euthymics Bioscience Inc. It is a so-called triple reuptake inhibitor (TRI) or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).
It is the (+)-enantiomer of DOV-216,303, and its (−)-enantiomer is DOV-102,677. Ki values for SERT, NET, and DAT are 99 nM, 262 nM, and 213 nM. The IC50 values for serotonin, norepinephrine and dopamine uptake are 12, 23 and 96 nM, respectively
Amitifadine reduces the duration of immobility in the forced swim test in rats with an oral minimum effective dose (MED) of 5 mg/kg. This antidepressant-like effect manifests in the absence of significant increases in motor activity at doses of up to 20 mg/kg. Amitifadine also produces a dose-dependent reduction in immobility in the tail suspension test, with an oral MED of 5 mg/kg. In microdialysis studies, amitifadine increased extracellular levels of serotonin, norepinephrine and dopamine in brain regions and did not induce hyperactivity in rats. Results in a small clinical trial indicated that amitifadine had statistically significant antidepressant effects and was well tolerated.